Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View

Shares of Novartis have risen 10.7% year to date compared with the industry's growth of 23.4%. In October 2023, Novartis completed the spin-off of its generic and biosimilar unit, Sandoz, following which the latter became an independent company. The results of the Sandoz division and selected portions of corporate activities attributable to the Sandoz business are reported as discontinued operations. Cosentyx's sales (psoriasis, spondylitis and arthritis) increased 22% to $1.5 billion, which beat the Zacks ...